Cytosorbents (CTSO) Net Cash Flow (QoQ) (2010 - 2026)
Cytosorbents (CTSO) Net Cash Flow (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.03 Bn | 175.74 Bn | 6.27 Bn |
| 2 | Stryker | 129.38 Bn | 126.50 Bn | 3.81 Bn |
| 3 | Medtronic | 108.86 Bn | 99.64 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.57 Bn | 67.12 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 47.66 Bn | 43.99 Bn | 1.29 Bn |
| 6 | Dexcom | 28.64 Bn | 27.52 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.55 Bn | 26.27 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 27.02 Bn | 26.44 Bn | - |
| 9 | Koninklijke Philips | 25.54 Bn | 22.42 Bn | 2.07 Bn |
| 10 | Cytosorbents | 23.46 Mn | 18.66 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 54.21% |
| Dec 31, 2025 | -4.60% |
| Sep 30, 2025 | -53.69% |
| Jun 30, 2025 | -149.46% |
| Mar 31, 2025 | 244.39% |
| Dec 31, 2024 | 19.68% |
| Sep 30, 2024 | -158.13% |
| Jun 30, 2024 | 189.02% |
| Mar 31, 2024 | -197.55% |
| Dec 31, 2023 | 217.68% |
| Sep 30, 2023 | 17.85% |
| Jun 30, 2023 | -88.68% |
| Mar 31, 2023 | -468.59% |
| Dec 31, 2022 | 92.67% |
| Sep 30, 2022 | 41.44% |
| Jun 30, 2022 | -41.27% |
| Mar 31, 2022 | -24.32% |
| Dec 31, 2021 | -58.84% |
| Sep 30, 2021 | -57.77% |
| Jun 30, 2021 | -0.59% |